LEXINGTON, Mass.--(BUSINESS WIRE)--April 26, 2007--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it will be presenting at the upcoming Acumen/BioFin Rodman and Renshaw 4th Annual Global Healthcare Conference. Safi Bahcall, Ph.D., President and CEO, will discuss the Company's oncology and inflammation drug discovery and development programs. The Synta presentation will begin at 2:55 PM (GMT) on Tuesday, May 15, 2007 and the Conference will be held at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

The presentation will be available via live audio webcast on the Company's website at www.syntapharma.com.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. The company's lead drug candidate, STA-4783, is an oxidative stress inducer which recently completed a double-blind, multi-center randomized Phase 2b clinical trial in metastatic melanoma and will be entering Phase 3 development in 2007. All Synta drug candidates were discovered and developed internally. For more information, please see www.syntapharma.com. SNTA-G

Safe Harbor Statement

This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in Item 1A "Risk Factors" of our Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

    CONTACT: Synta Pharmaceuticals Corp.
             Rob Kloppenburg, 781-541-7125
             or
             MacDougall Biomedical Communications
             Doug MacDougall, 508-647-0209

    SOURCE: Synta Pharmaceuticals Corp.